Details of the Drug

General Information of Drug (ID: DMSGA6Z)

Drug Name
Toripalimab
Indication
Disease Entry ICD 11 Status REF
Demodex blepharitis 1G07 Approved in China [1]
Melanoma 2C30 Approved in China [1]
Urothelial carcinoma 2C92.0 Approved in China [1]
Esophageal squamous cell carcinoma 2E60.1 Phase 3 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D92OCI
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
2 ClinicalTrials.gov (NCT03829969) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy. U.S.National Institutes of Health.
3 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.